Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement ...

Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...

Dynamic interactions between renewable energy sources and power grids are prone to wideband oscillations, which threaten the safe and stable operation of power systems and require effective ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...

Among immunocompromised patients receiving immunoglobulin replacement therapy, the subcutaneous route of immunoglobulin administration shows lower infection rates than other routes.

SAN DIEGO, CA- June 24, 2025- Axim Biotechnologies, Inc., a leading developer of rapid diagnostic testing for ocular and systemic conditions, today announced that it has filed a Pre-Submission ...